Skip to main content
. 2018 Aug 1;127:334–340. doi: 10.1016/j.appet.2018.05.131

Fig. 1.

Fig. 1

GLP-1:CCK fusion peptide C2816 is an agonist at both GLP-1 and CCK receptors. Concentration–response curves for peptide induced increase in cAMP accumulation in CHO-hGLP-1R cells (A) and increase in beta-arrestin recruitment in CHO- hCCK-1R cells (B). Data shown are individual data points (B) or mean (±SD) of duplicate (A) fitted with 4-parameter logistic fit to determine EC50 and are representative of at least three independent repeats.